Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.
Increased coffee consumption appears to lower the risk of colon adenoma, results of a meta-analysis have shown. However, this association should be carefully considered due to latent confusion and different exposure classification.
Four cycles of the chemotherapeutic regimen comprising cyclophosphamide, doxorubicin, vincristine, and prednisone plus six cycles of rituximab (R-CHOP) are noninferior to the standard six cycles of R-CHOP for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) in young patients (≤60 years) with a favourable risk profile, the FLYER trial shows.
Administering a short course of androgen suppression in addition to salvage radiotherapy (RT) yields a substantial increase in survival in prostate cancer patients with increasing prostate-specific antigen (PSA) concentration following radical prostatectomy as compared with RT alone, according to long-term data from the phase III GETUG-AFU 16 trial.
Adding pegilodecakin, a pegylated form of interleukin-10 (IL-10), to second-line FOLFOX chemotherapy does not significantly improve overall survival (OS) or other outcomes in patients with advanced pancreatic ductal adenocarcinoma (PDAC) as compared with FOLFOX alone, results of the phase III SEQUOIA trial have shown.
Ofatumumab proves to be useful in the maintenance treatment of patients with relapsed chronic lymphocytic leukaemia (CLL), according to the final analysis of the phase III PROLONG trial, which has shown that the regimen is well tolerated and substantially extends progression-free survival (PFS).
Performing transarterial chemoembolization (TACE) in addition to sorafenib therapy yields a significant increase in progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) when compared with TACE alone, according to the results of the TACTICS* trial.
The third-generation tyrosine kinase inhibitor lorlatinib appears to be safe and have potent therapeutic effect in advanced nonsmall-cell lung cancer (NSCLC) harbouring ROS1 mutation, including patients with central nervous system metastases and those with previous crizotinib exposure, according to the results of a phase I/II trial.
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).